Surmodics Inc. (SRDX)
NASDAQ: SRDX
· Real-Time Price · USD
27.85
-0.16 (-0.57%)
At close: May 01, 2025, 3:57 PM
27.86
0.04%
After-hours: May 01, 2025, 04:00 PM EDT
-0.57% (1D)
| Bid | 27.5 |
| Market Cap | 398.14M |
| Revenue (ttm) | 125.45M |
| Net Income (ttm) | -14.41M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -27.3 |
| Forward PE | 121.74 |
| Analyst | Hold |
| Ask | 28.56 |
| Volume | 56,338 |
| Avg. Volume (20D) | 186,883 |
| Open | 27.71 |
| Previous Close | 28.01 |
| Day's Range | 27.55 - 28.25 |
| 52-Week Range | 26.00 - 42.44 |
| Beta | 1.30 |
About SRDX
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliver...
Industry Medical - Devices
Sector Healthcare
IPO Date Mar 4, 1998
Employees 389
Stock Exchange NASDAQ
Ticker Symbol SRDX
Website https://www.surmodics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for SRDX stock is "Hold." The 12-month stock price forecast is $43, which is an increase of 54.40% from the latest price.
Stock ForecastsEarnings Surprise
Surmodics has released their quartely earnings
on Apr 30, 2025:
1 day ago
-9.44%
Surmodics shares are trading lower. The company re...
Unlock content with
Pro Subscription
11 months ago
+19.94%
Surmodics shares are trading higher after the company announced it will be acquired by GTCR for $43 per share in cash for a total equity valuation of roughly $627 million.
